Clinical Trial Search Results

Click on the name (title) to see the trial details in the LRG database. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database.

9 trials found

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: First-line
Status:  Recruiting
Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Léon Bérard Lyon Rhone France
Istituto Nazionale Dei Tumori Milan Italy
Universita Campus Bio-Medico di Roma Rome Italy
Hospital Universitario de Canarias Tenerife Spain
Hospital Vall d'Hebron Barcelona Spain
Hospital Santa Creu i Sant Pau Barcelona Spain
University Hospital La Paz Madrid Spain
hospital Universitario Miguel Servet Zaragosa Spain
Instituto di Candiolo - IRCSS Torino Italy
Hospital de Cruces Barakaldo Spain
Hospital Universitario Gregorio Maranon Madrid Spain
Hospital Universitario Virgen de la Macarena Sevilla Spain
Instituto Valencia de Oncologia Valencia Spain
Hospital Virgen del Rocio Sevilla Spain


Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: First-line
Status:  Completed
Site
City
State
Country


Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: Gleevec-resistant
Status:  Recruiting
Site
City
State
Country
Moores Cancer Center/UCSD Medical center La Jolla CA USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA


A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer
Phase:   2
 
Drug Category:  SDH-directed
Conditions: SDH- GIST
Treatment Phase: First-line
Status:  Completed
Site
City
State
Country
National Cancer Institute Bethesda MD USA


Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase:   1
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
University of Pennsylvania Philadelphia PA USA
Memorial Sloan Kettering New York NY USA
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA USA
Stanford University Medical Center Palo Alto CA USA
Florida Cancer Specialists Sarasota FL USA
Tennessee Oncology Nashville TN USA
Emory Winship Cancer Institute Atlanta GA USA
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
National Cancer Institute Bethesda MD USA


Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Phase:   1/2
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Terminated
Site
City
State
Country
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA
UAB Comprehensive Cancer Center Birmingham AL USA
Emory Winship Cancer Institute Atlanta GA USA
University of Iowa Hospitals and Clinics Iowa City IA USA
Massachusetts General Hospital Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
MD Anderson Cancer Center Houston TX USA
Huntsman Cancer Institute Salt Lake City UT USA
Carbone Cancer Center, University of Wisconsin Madison WI USA


Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Recruiting
Site
City
State
Country
H. Lee Moffit Cancer Center Tampa FL USA
Warren Grant Magnuson Clinical Center Bethesda MD USA
Dana Farber Cancer Institute Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
MD Anderson Cancer Center Houston TX USA
Moffitt Cancer Center-International Plaza Tampa FL USA
University of Kentucky/Markey Cancer Center Lexington KY USA


Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Terminated
Site
City
State
Country
Eastchester Center for Cancer Bronx NY USA


A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors
Phase:   1
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Wake Forrest Winston-Salem NC USA
Tennessee Oncology Nashville TN USA
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA


9 trials found